Mail to a Friend

Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by hATTR Amyloidosis

2021-01-21 11:32:14 Health and Fitness


Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) experienced sustained improvements in measures of neuropathic progression at 39 months of therapy compared to the natural history of the disease.
Patients administered TEGSEDI also experienced clinically relevant improvements in measures of quality of life compared to the natural history of the disease.
No new safety signals were identified in the OLE study.

Company :-Akcea Therapeutics Inc.

User :- Akcea Therapeutics


Phone :-(617) 207-0202

Url :-


Related Post


Online assignment help by Copycrafter will free you from any academic issues